| Technical Name | Drug Discovery of Development of Highly Selective HDAC6 Inhibitor MPT0G211 | ||
|---|---|---|---|
| Project Operator | Taipei Medical University | ||
| Project Host | 潘秀玲 | ||
| Summary | The invention concerns a novel, first-in class, and oral small molecule HDAC6 Inhibitor, MPT0G211, which has been shown to be a potential therapeutic for cancer and neurodegenerative diseases. |
||
| Scientific Breakthrough | Three HDAC6 inhibitors are in clinical trials for cancer treatment. MPT0G211 has superior selectivity and sensitivity than competitors, and well tolerated without cardiac toxicity. Current two marketed AD drugs only relieve symptoms with side effects; while MPT0G211 can block pathological factors, β-amyloid and p-Tau. These are great advantages over other HDAC6 inhibitors on the market. |
||
| Industrial Applicability | MPT0G211 will finish IND enabling studies around Q3 2020 and enter Phase I clinical trials around Q4 2020. MPT0G211 is currently testing for the therapeutic potential in cancer, neuropathic pain and neurodegenerative diseases. These are great advantages of MPT0G211 on the market. The market potential of MM and AD will be $12.0 billion USD by 2024 and $12.6 billion USD by 2023. |
||
| Keyword | MPT0G211 Selective Histone deacetylase 6 Small molecule inhibitor New drug discovery and development Multiple myeloma Cancer Neurodegenerative diseases Preclinical study Early stage | ||
| Notes | |||
- Contact
- hlhuang@tmu.edu.tw
other people also saw
